Macquarie Group’s Kura Oncology KURA Stock Holding History

Macquarie Group’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-469	Closed	-$6K	–	1733
2022 Q4	$6K	Sell	469 -517	-52%	-$7.51K	﹤0.01%	1731
2022 Q3	$26K	Sell	986 -478	-33%	-$7.37K	﹤0.01%	2129
2022 Q2	$27K	Hold	1,464	–	–	﹤0.01%	2217
2022 Q1	$24	Hold	1,464	–	–	﹤0.01%	2345
2021 Q4	$20K	Hold	1,464	–	–	﹤0.01%	2393
2021 Q3	$27K	Hold	1,464	–	–	﹤0.01%	2385
2021 Q2	$31K	Hold	1,464	–	–	﹤0.01%	2255
2021 Q1	$41K	Sell	1,464 -449	-23%	-$14.2K	﹤0.01%	2123
2020 Q4	$62K	Hold	1,913	–	–	﹤0.01%	1990
2020 Q3	$59K	Hold	1,913	–	–	﹤0.01%	1920
2020 Q2	$31K	Buy	+1,913	New	+$27.6K	﹤0.01%	2047
2019 Q1	–	Sell	-300	Closed	-$4K	–	1859
2018 Q4	$4K	Hold	300	–	–	﹤0.01%	2134
2018 Q3	$5K	Buy	+300	New	+$5.75K	﹤0.01%	2067
2018 Q1	–	Sell	-600	Closed	-$9K	–	2272
2017 Q4	$9K	Buy	+600	New	+$8.84K	﹤0.01%	2277

Other funds holding KURA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Macquarie Group's KURA Position: Q1 2023 in Review

Macquarie Group sold out of Kura Oncology (KURA) in Q1 2023, closing a stake of 469 shares — an estimated $6K sold.

Macquarie Group first reported a position in KURA in Q4 2017 and held it in 14 quarters. The position peaked at $62K in Q4 2020. 141 funds tracked by Wall St. Rank hold KURA as of Q1 2023.

Macquarie Group reported no remaining Kura Oncology position as of Q1 2023 after selling out during the quarter.
Macquarie Group sold 469 Kura Oncology shares in Q1 2023, an estimated $6K.
Macquarie Group first reported a position in Kura Oncology in Q4 2017 and held it in 14 quarters.
Macquarie Group's Kura Oncology position peaked at $62K in Q4 2020.
141 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2023.

Based on Macquarie Group's 13F filing for Q1 2023, filed 15 May 2023.